Annual trends of cystectomy complications: A contemporary analysis of the NSQIP database.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
09 2023
Historique:
received: 22 01 2023
revised: 19 03 2023
accepted: 24 03 2023
medline: 12 9 2023
pubmed: 29 5 2023
entrez: 28 5 2023
Statut: ppublish

Résumé

Despite significant morbidity, radical cystectomy (RC) is standard of care for muscle invasive bladder cancer, certain high-risk nonmuscle invasive tumors and after failure of intravesical or trimodal therapy. Modern efforts have hastened the recovery after this surgery without impact on overall complication rates. Our primary aim was to examine changes in complication rates of RC over time. The National Surgical Quality Improvement Program database included 11,351 RC from 2006 to 2018 for nondisseminated bladder cancer. Baseline characteristics and complication rates were studied across time periods: 2006 to 2011, 2012 to 2014, and 2015 to 2018. Thirty-day complications, readmissions, and mortality were identified. Overall complication rates decreased over time (56.5%, 57.4%, 50.6%, P < 0.01). Infectious complications were stable, including UTIs (10.1%, 8.8%, 8.3% respectively, P = 0.11) and sepsis (10.4%, 8.8%, 8.7% respectively, P = 0.20). On multivariable analysis, ASA≥3 (OR 1.399, 95% CI 1.279-1.530) was associated with increased complications, while procedures in 2015 to 2018 (OR 0.825, 95% CI 0.722-0.942), laparoscopic/robotic approach (OR 0.555, 95%CI 0.494-0.622), and ileal conduit (OR 0.796, 95% CI 0.719-0.882) were associated with decreased complication rates. Other outcomes of interest included mean length of stay (LOS), which decreased over time (10.5, 9.8, 8.6 days, respectively, P < 0.01) and readmission (20.0%, 21.3%, 21.0%, respectively, P = 0.84) and mortality rates were stable (2.7%, 1.7%, 2.0%, respectively, P = 0.13). Decreased early complications and LOS after RC over time may reflect beneficial effects of recent advances in bladder cancer treatment such as enhanced recovery after surgery protocols and minimally invasive techniques. Further opportunities to improve long term outcomes, readmissions and infection rates are needed.

Identifiants

pubmed: 37246134
pii: S1078-1439(23)00105-9
doi: 10.1016/j.urolonc.2023.03.014
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

390.e19-390.e26

Subventions

Organisme : NCI NIH HHS
ID : P30 CA072720
Pays : United States

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The American College of Surgeons National Surgical Quality Improvement Program and the hospitals participating in the ACS NSQIP are the source of the data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.

Auteurs

Kevin J Chua (KJ)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

Hiren V Patel (HV)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

Arnav Srivastava (A)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

Sai Krishnaraya Doppalapudi (SK)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

Benjamin Lichtbroun (B)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

Nikhil Patel (N)

Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Sammy E Elsamra (SE)

Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Eric A Singer (EA)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Division of Urologic Oncology, The Ohio State Comprehensive Cancer Center, Columbus, OH.

Thomas L Jang (TL)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

Saum B Ghodoussipour (SB)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. Electronic address: sg1621@cinj.rutgers.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH